Varian IMRT Technology Makes Investors Beam; Stock Up 18% In Q2
This article was originally published in The Gray Sheet
The growing demand for advanced radiation therapy systems in the U.S. combined with a predictable revenue stream made Varian Medical Systems an investor favorite in the second quarter. The firm's stock price rose 10.70 points (17.6%) during the three months ended June 29 to $71.50.
You may also be interested in...
Guidant's Contak CD "continued access policy" IDE could augment the company's pivotal trial and allow the firm to avoid returning for a second review by the Circulatory System Devices Panel.
Pain relief product sales grew 27% and upper respiratory sales 35% for the week ended 7 March as consumers respond to COVID-19, according to Nielsen data noted in a Jefferies report on consumer health purchasing trends. Private label market share is up slightly, while OTC purchases continue primarily in conventional stores.
Managing partner Corey Goodman said venBio didn’t have trouble closing its fund, because the venture capital firm prepared its investors for an economic downturn months ago.